Australia markets open in 7 hours 1 minute

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
18.81+0.60 (+3.29%)
As of 10:58AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close18.21
Open18.05
Bid18.54 x 1300
Ask18.60 x 1400
Day's range17.91 - 18.85
52-week range12.90 - 39.12
Volume174,223
Avg. volume1,910,746
Market cap2.681B
Beta (5Y monthly)0.78
PE ratio (TTM)N/A
EPS (TTM)-1.88
Earnings date23 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est35.19
  • GlobeNewswire

    Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting

    Conference Call and Webcast Scheduled for Monday, December 13, 2021 at 1:30 PM PT/4:30 PM ET SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will host a conference call to review data to be presented at the American Society of Hematology Annual Meeting from the ALPHA and ALPHA2 Phase 1 t

  • GlobeNewswire

    Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in five upcoming virtual investor conferences. Cowen's 5th Annual IO Next SummitMonday, November 15, 20218:45 AM PT/11:45 AM ET Stifel 2021 Virtual Healthcare ConferenceTuesday, November 16, 202111:00 AM PT/2:00 PM ET J

  • Motley Fool

    Cathie Wood's Buying Beam Therapeutics -- Should You?

    Over the past year, shares of Beam Therapeutics (NASDAQ: BEAM) have soared over 174% higher. This is the firm founded and still run by Cathie Wood, one of the world's most famous investors. Beam Therapeutics is pioneering the use of a new base editing technique in the development of new gene therapies.